As with antiretroviral combinations used in treatment, passive immunization of broadly neutralizing antibodies for prevention may require two or more bNAbs that target different parts of the virus. This graphic outlines the bNAb combinations being explored in early clinical studies.
Broadly Neutralizing Antibody Combinations
AMP Study FAQ
From the two trial networks conducting the AMP Study, this document provides answers to commonly asked questions about the VRC01 antibody, details on the study design and more.
AVAC’s World AIDS Day 2020 Letter to the World
On World AIDS Day 2020, AVAC hones in on three things that are essential advocacy priorities for the present moment and in 2021.
• Program for choice.
• Pay for the healthcare workforce to achieve health equity.
• Pursue just, equitable access for COVID-19 vaccines, therapeutics and community-led prevention.
Advocate’s Guide To COVID-19 Vaccine Access
The Advocate’s Guide provides plain-language explanations of the necessary components for equitable COVID-19 vaccine access to help inform and support advocates.
Biomedical HIV Prevention Trials: Results, milestones and more
This graphic shows the updated status of large-scale prevention trials through 2022 and the impact of COVID-19 on each trial.
Another version of this graphic is available here (same content, different visual Treatment U=U).
Public Comment from Mitchell Warren, Executive Director, AVAC At the Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting
Comments made by Mitchell Warren to the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting on October 22, 2020 about COVID-19 vaccine development and use authorization.
The Next-Generation of Biomedical Prevention: Now What
Slides presented by AVAC Executive Director Mitchell Warren at the PEPFAR Scientific Advisory Board meeting taking place over October 7-8, 2020.
Understanding the EMA Opinion and Next Steps for the Dapivirine Vaginal Ring
On July 24, 2020, the European Medicines Agency (EMA) announced a positive regulatory opinion from on the Dapivirine Vaginal Ring as an HIV prevention option for cisgender women age 18 and older. This document helps advocates to understand the steps that can and must be taken now that the EMA has provided its opinion. Read it here.
Global Investment in HIV Cure Research and Development in 2019
In 2014, the HIV Vaccines and Microbicides Resource Tracking Working Group and AVAC began a
A Leap Forward For the Dapivirine Vaginal Ring, the Next Steps Are Critical
After decades of research and advocacy, the Dapivirine Vaginal Ring is now one step closer to becoming available as a discreet, woman-initiated HIV prevention option. In July, the European Medicines Agency (EMA) issued a positive opinion for the ring, allowing the next steps in the regulatory process to go forward. Download this podcast to hear five different perspectives on the ring, how it expands HIV prevention options for women, and the most important next steps to bring the ring to women who need it.